Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company was founded in 1969 and is based in Washington, the District of Columbia.
DHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Danaher Corp. To summarize, we found that Danaher Corp ranked in the 21th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Danaher Corp ended up being:
DHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 28.47% of tickers in our DCF set.
The weighted average cost of capital for the company is 7. This value is greater than only 14.15% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
BAX, ELMD, MTD, PBYI, and NRC can be thought of as valuation peers to DHR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
I've been a skeptic toward General Electric (NYSE:GE) stock for some time now. Truthfully, I'm not too happy about it.Source: Sundry Photography / Shutterstock.com After all, General Electric once was one of America's greatest and most innovative companies. It provided thousands of employees with stable jobs and generous retirement plans. GE stock was a core holding of pension funds and individual investors.Sadly, that's no longer the case. General Electric offers many fewer jobs: its workforce shrunk 28% worldwide in 2019. And GE stock, almost incredibly, touched a 29-year low this month. Its dividend has been cut -- twice.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe reality is sad. But it's still the reality. Investors need to react accordingly. * 7 Red-Hot Vacci...
Beckman Coulter Life Sciences today announced RNAdvance Viral XP has been added to the list of acceptable extraction methods for use in the Centers for Disease Control's EUA-authorized COVID-19 test referenced in the FDA's FAQ on testing for SARS-CoV-2. Laboratories are now permitted to independently validate RNAdvance Viral XP for use.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Danaher Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Beckman Coulter announced today the availability of its DxH 690T hematology analyzer in the U.S. Designed to streamline workflow and minimize downtime in mid-volume laboratories, the DxH 690T delivers all of the benefits of the company's flagship DxH 900 large-volume hematology analyzer in a table-top configuration.